Blood stream infection is a condition where any bacterial, fungal or any type of infection is detected in the blood. The condition is evident when the infection enters into the blood stream of any part of the body. The bacteria or organisms that causes the blood infection are determined by using blood stream infection testing. There is major risk to human health because as there is rise in human population the hygiene level lowers which leads to the occurrence of various infectious diseases. According to the World Bank 2016 report, the population has reached up to 7.44 billion globally. This rising population leads to fuel the growth of the blood stream infection testing market. Self-diagnosis of bloodstream infections is difficult to because of its common symptoms like chills, cold, fever, diarrhea, vomiting. This reasons are needed to make testing mandatory for the detection of the infection in the bloodstream. This leads to boost the market growth. The blood stream infection tester tracks antibiotic resistance markers in bacteria. It is also used to diagnose sepsis.
The global blood stream infection testing market size was valued at US$ 3,758.7 million in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2019 – 2026).
Figure 1. Blood Stream Infection Testing Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of abdominal infection, dental infection, and chronic diseases is expected to propel the blood stream infection testing market growth
Overpopulated and insufficient shelters are the major factors causing transmission of diseases. Moreover, increasing awareness about chronic diseases such as cancer, HIV, and pneumonia that require blood tests at regular intervals of time is expected to boost growth of the market. Innovations, research and development investments, mergers and acquisitions of the key vendors help to boost growth of the blood stream infection testing market.
High demand for technologically advanced diagnostic tests, awareness about hygiene, diagnosis rate and unhealthy lifestyle are also expected to fuel the market growth over the forecast period.
However, rigid regulatory scenario related to diagnostic procedures, high diagnosis cost and lack of medical reimbursement may hinder the bloodstream infection testing market.
Figure 2. Blood Stream Infection Testing Market Share (%), by Product Type 2018 and 2026
Source: Coherent Market Insights Analysis (2019)
Geographical expansion of blood stream infection testing manufacturers towards North America boost the market growth
On the basis of region, the global blood stream infection testing market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America held the dominant position in the global blood stream infection testing market in 2018, owing to preventive healthcare awareness and high adoption of the innovative products. Moreover, high diagnosis rate and developed medical facilities in this region also drives the growth of blood stream infection testing market in North America.
Moreover, Asia Pacific is expected to witness higher growth in the forecast period, owing to high prevalence of chronic diseases in the region. The wide availability of innovative products offering better solutions to patients at marginally lower costs also drives the blood stream infection testing market growth. For instance, in 2017, a group of researchers led by the National Cancer Center Japan (NCC), together with Toray Industries, Inc., developed a new method that could detect thirteen different cancer types with a single drop of blood.
Moreover, For instance, in 2017, Luminex Corporation announced that Japan’s Central Social Insurance Medical Council approved to provide reimbursement for two VERIGENE assays: the gram positive and negative blood culture test. This reimbursement is recommended by the Japanese Ministry of Health, Labor and Welfare. The VERIGENE system is able to detect pathogens from blood stream for various infectious diseases.
Major players operating in the blood stream infection testing market include, BioMérieux SA, Becton, Dickinson and Company, AB Sciex, IRIDICA, Abbot Laboratories, Cepheid Inc., C. R. Bard, Inc., F. Hoffmann-La Roche AG, Nanoshpere, Dade Behring, AdvanDX, and Siemens Healthcare.
Blood stream infection is a condition in which the blood is detected with bacterial, fungal, or any other infection. This condition normally occurs when the infection enters the blood stream of any part of body through wound, injection or during any surgical procedures. This infection is also considered as blood poisoning, bacteremia, septicemia, or sepsis. Self-diagnosis of blood stream infections is difficult, owing to its common symptoms (such as chills, fever, diarrhea, vomiting, and others), thereby testing is mandatory for detection of infections in blood.
Increasing prevalence of infections such as abdominal infections, dental infections, kidney and urinary infection, and chronic diseases drives the market growth. According to the World Health Organization (WHO), in 2016, over 30 million people are affected by sepsis worldwide, annually, leading to 6 million deaths. Moreover, increasing R&D investments related to blood stream infection testing is also expected to boost the market growth. Moreover, high incidences of burns/wounds cases, HIV, pneumonia, pyelonephritis, and cancer along with growing awareness about hygiene is also expected to boost the global blood stream infection testing market growth. According to World Health Organization, at the end of 2017, approximately 36.9 million people living with HIV and 1.8 million people becoming newly ininfected in 2017 globally. However, the high diagnostic costs and insufficiency medical reimbursement may hinder the market growth.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.